Pyxis Oncology Provides Corporate and Financial Update
Pyxis Oncology (PYXS) has expanded its immuno-oncology pipeline with the in-licensing of anti-Siglec-15 (now PYX-106) from Biosion and the introduction of its first internally developed candidate, anti-KLRG1 (PYX-102). The company reported cash reserves of approximately $253 million, expected to fund operations through Q3 2024, and aims to file INDs for various candidates in the upcoming years. R&D expenses rose to $51.1 million in 2021, reflecting investments in multiple antibody-drug conjugates. The net loss was $76 million, primarily due to these developments.
- In-licensed anti-Siglec-15 (PYX-106) from Biosion, enhancing the immuno-oncology pipeline.
- Introduced first internally developed candidate, anti-KLRG1 (PYX-102).
- Strong cash position of approximately $253 million, funding operations into Q3 2024.
- Expecting multiple IND filings through 2022 and 2023, signaling continued development.
- Net loss of $76 million in 2021, significantly increasing from $12.8 million in 2020.
- R&D expenses surged to $51.1 million, indicating higher operational costs without revenue generation.
Announces Expansion of Novel Immuno-Oncology Therapeutic Portfolio with Addition of Anti-Siglec-15 In-licensed from Biosion (PYX-106)
Introduces First Internally Developed IO Candidate Anti-KLRG1 (PYX-102)
Cash Runway Sufficient for Multiple Milestones Through Third Quarter 2024
Company to Host Conference Call and Webcast Today at 8:00 a.m. ET
CAMBRIDGE, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today provided a corporate and financial update and reported financial results for the full year ended December 31, 2021.
“We have had a highly productive start to 2022, advancing our lead programs toward first-in-human clinical trials while executing our strategy of identifying the most promising scientific breakthroughs and therapeutics in the treatment of cancers,” said Lara Sullivan, M.D., Chief Executive Officer of Pyxis Oncology. “The in-licensing of Biosion’s anti-Siglec-15 (PYX-106) and the introduction of our first internally developed candidate anti-KLRG1 (PYX-102) further validate our approach to portfolio and pipeline expansion by identifying and progressing some of the most promising scientific and clinical advances from either our internal discovery engines or external sources.”
“We are excited to partner with Pyxis Oncology and its experienced management team for the development of this promising asset,” said Hugh M. Davis, Ph.D., Chief Operating Officer, Biosion, Inc. and President, Biosion USA, Inc. “While immunotherapies have improved the lives of many patients, only a fraction respond to treatment, suggesting that our understanding of how cancer is able to evade the immune system is incomplete. We believe that anti-Siglec-15 may represent a breakthrough and that targeting siglec-15 could extend the benefits of immunotherapies to broader patient populations, including those who have failed PD-(L)1 targeting therapies.”
Corporate Development Highlights
- License agreement with Biosion adds anti-Siglec-15 to Pyxis Oncology’s IO pipeline: Pyxis Oncology announced today it has in-licensed anti-Siglec-15, now referred to as PYX-106, a potentially best-in-class monoclonal antibody which is a novel immune checkpoint. In pre-clinical studies, PYX-106 is broadly expressed across a range of solid tumors among difficult-to-treat cancers. The American Academy for Cancer Research (AACR) has accepted an abstract submitted by Biosion for PYX-106. The poster will be made available at the start of the AACR Annual Meeting on April 8, 2022. Pyxis Oncology expects to file an IND for PYX-106 in the second half of 2022.
- Pipeline expansion with the addition of Company’s first internally developed candidate: Pyxis Oncology announced today the declaration of its first internally developed candidate, an anti-KLRG1 monoclonal antibody program now referred to as PYX-102. PYX-102 originated as part of the Company’s proprietary IO target catalog and work out of Pyxis Oncology founder Tom Gajewski’s lab at the University of Chicago. The Company expects to provide further updates closer to the planned IND submission for PYX-102 in the second half of 2023.
- Additional GLP study underway for PYX-202: Pyxis Oncology’s anti-DLK1 ADC, PYX-202, was licensed in from LegoChem Biosciences, Inc. in December 2020. In preparation for an IND filing and based on observation of the Company’s GLP studies to date, management has decided to conduct additional GLP and non-GLP toxicity studies to determine whether PYX-202 is a viable clinical candidate. The Company will continue to monitor the progress of its PYX-202 program and expects to provide an update about PYX-202 in mid-2022.
- Advancing programs toward the clinic with near-term catalysts: Pyxis Oncology expects to file INDs for anti-EDB, PYX-201, and anti-CD123, PYX-203, in the second half of 2022 and in the second half of 2023, respectively.
Financial Update
- As of March 29, 2022, Pyxis Oncology had cash and cash equivalents of approximately
$253 million (preliminary, unaudited), which is expected to fund operations into the third quarter of 2024.
“With a solid balance sheet and cash runway sufficient to deliver multiple catalysts through the third quarter of 2024, we remain focused on building and advancing our pipeline through a multi-asset multi-modality approach that we believe will unlock benefits for patients,” said Pam Connealy, Chief Financial Officer.
- Research and development expenses for the full year ended December 31, 2021 were
$51.1 million , compared to$9.1 million for the full year ended December 31, 2020. The increase in research and development expenses was primarily attributed to increased expenses associated with the addition of three antibody-drug conjugates to the Company’s portfolio and an increase in employee headcount to support research and development activities. - General and administrative expenses for the full year ended December 31, 2021 were
$18.6 million , compared to$3.8 million for the year ended December 31, 2020. The increase was primarily attributed to higher personnel-related expenses (including stock-based compensation), and costs incurred to support the growth and expansion of the business, overhead and facilities. - Net loss for the full year ended December 31, 2021 was
$76.0 million ($8.95 per common share), compared to$12.8 million ($12.45 per common share) for the year ended December 31, 2020. The increase in net loss is primarily attributed to the addition of three antibody-drug conjugates to the Company’s portfolio and the Company’s preparations to initiate human clinical trials for PYX-201. - As of March 25, 2022, the outstanding number of shares of Common Stock of Pyxis Oncology was 32,841,747.
Conference Call and Webcast Details
Pyxis Oncology management will host a conference call and live webcast on Tuesday, March 29, 2022, at 8:00 a.m. ET to discuss recent corporate updates. The live call can be accessed by dialing (833) 945-2461 (domestic) or (520) 809-9726 (international) using the conference ID 5458057. A live webcast can be accessed at https://edge.media-server.com/mmc/p/c8uwd9dr or on the Investors section of the Pyxis Oncology website at ir.pyxisoncology.com. A replay of the webcast will be available approximately two hours after completion of the call and will be archived on the Company’s website for up to 45 days.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a multi-asset multi-modality company focused on defeating difficult to treat cancers and improving patient lives. By leveraging our fully integrated research, development and commercial capabilities, our expert team is efficiently building a diversified portfolio of next-generation therapeutics. Pyxis Oncology’s therapeutic candidates are designed to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since its launch in 2019, Pyxis Oncology has developed a broad portfolio of novel antibody-drug conjugate product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that it is developing as monotherapies and in combination with other therapies. To learn more about Pyxis Oncology, visit www.pyxisoncology.com.
Forward-Looking Statements
This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements are often identified by the use of words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “to be,” “will,” “would,” or the negative or plural of these words, or similar expressions or variations, although not all forward-looking statements contain these words. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified herein, and those discussed in the section titled “Risk Factors” set forth in Part I, Item 1A. of the Company's most recent Annual Report on Form 10-K and in our other filings with the SEC. These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.
Investor and Media Contact
Courtney Dugan
VP, Head of Investor Relations and Corporate Communications
ir@pyxisoncology.com
---tables to follow---
PYXIS ONCOLOGY, INC.
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
| Years Ended December 31, | ||||||||
| 2021 | 2020 | |||||||
| Operating expenses: | ||||||||
| Research and development | $ | 51,054 | $ | 9,048 | ||||
| General and administrative | 18,663 | 3,846 | ||||||
| Total operating expenses | 69,717 | 12,894 | ||||||
| Loss from operations | (69,717 | ) | (12,894 | ) | ||||
| Other (expense) income: | ||||||||
| Interest income | 23 | 66 | ||||||
| Service fee income from related party | 181 | — | ||||||
| Change in fair value of derivative liability | (6,231 | ) | — | |||||
| Total other (expense) income | (6,027 | ) | 66 | |||||
| Loss from equity method investment in joint venture | (231 | ) | — | |||||
| Net loss and comprehensive loss | $ | (75,975 | ) | $ | (12,828 | ) | ||
| Net loss per common share - basic and diluted | $ | (8.95 | ) | $ | (12.45 | ) | ||
| Weighted average shares of common stock outstanding - basic and diluted | 8,493,273 | 1,030,556 | ||||||
PYXIS ONCOLOGY, INC.
Consolidated Balance Sheets
(In thousands)
| December 31, | ||||||||
| 2021 | 2020 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 274,735 | $ | 8,080 | ||||
| Restricted cash | 1,472 | — | ||||||
| Prepaid expenses and other current assets | 2,466 | 23 | ||||||
| Total current assets | 278,673 | 8,103 | ||||||
| Property and equipment, net | 1,007 | 1,103 | ||||||
| Operating lease right-of-use assets | 232 | 836 | ||||||
| Other assets, noncurrent | 109 | 109 | ||||||
| Total assets | $ | 280,021 | $ | 10,151 | ||||
| Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 11,951 | $ | 1,077 | ||||
| Accrued expenses and other current liabilities | 6,592 | 1,997 | ||||||
| Operating lease liabilities, current portion | 165 | 615 | ||||||
| Total current liabilities | 18,708 | 3,689 | ||||||
| Operating lease liabilities, net of current portion | — | 165 | ||||||
| Total liabilities | 18,708 | 3,854 | ||||||
| Commitments and contingencies | ||||||||
| Series A Convertible Preferred Stock | — | 21,942 | ||||||
| Series B Convertible Preferred Stock | — | — | ||||||
| Stockholders’ equity (deficit): | ||||||||
| Preferred stock | — | — | ||||||
| Common stock | 32 | 1 | ||||||
| Additional paid-in capital | 352,999 | 97 | ||||||
| Accumulated deficit | (91,718 | ) | (15,743 | ) | ||||
| Total stockholders’ equity (deficit) | 261,313 | (15,645 | ) | |||||
| Total liabilities, convertible preferred stock and stockholders’ equity (deficit) | $ | 280,021 | $ | 10,151 | ||||
FAQ
What recent developments did Pyxis Oncology announce on March 29, 2022?
How much cash does Pyxis Oncology currently have?
What is the expected timeline for filing INDs for Pyxis Oncology's candidates?
What were the financial results for Pyxis Oncology for the year ended December 31, 2021?
